[go: up one dir, main page]

CL2013002210A1 - Formulación prebiótica para consumo humano que comprende 2´-fucosilactosa, 3´-sialilactosa y 6´-sialilactosa, en que la cantidad en peso de 3´-sialilactosa es al menos igual de elevada que la cantidad de 2´-fucosilactosa; y método para modular o estimular la proliferación de bifidobacterias en el intestino humano. - Google Patents

Formulación prebiótica para consumo humano que comprende 2´-fucosilactosa, 3´-sialilactosa y 6´-sialilactosa, en que la cantidad en peso de 3´-sialilactosa es al menos igual de elevada que la cantidad de 2´-fucosilactosa; y método para modular o estimular la proliferación de bifidobacterias en el intestino humano.

Info

Publication number
CL2013002210A1
CL2013002210A1 CL2013002210A CL2013002210A CL2013002210A1 CL 2013002210 A1 CL2013002210 A1 CL 2013002210A1 CL 2013002210 A CL2013002210 A CL 2013002210A CL 2013002210 A CL2013002210 A CL 2013002210A CL 2013002210 A1 CL2013002210 A1 CL 2013002210A1
Authority
CL
Chile
Prior art keywords
sialylactose
fucosylactose
amount
human
bifidobacteria
Prior art date
Application number
CL2013002210A
Other languages
English (en)
Inventor
Davis Curtis Frantz
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45809349&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013002210(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of CL2013002210A1 publication Critical patent/CL2013002210A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
    • A23C9/1307—Milk products or derivatives; Fruit or vegetable juices; Sugars, sugar alcohols, sweeteners; Oligosaccharides; Organic acids or salts thereof or acidifying agents; Flavours, dyes or pigments; Inert or aerosol gases; Carbonation methods
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pediatric Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dairy Products (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CL2013002210A 2011-02-10 2013-08-01 Formulación prebiótica para consumo humano que comprende 2´-fucosilactosa, 3´-sialilactosa y 6´-sialilactosa, en que la cantidad en peso de 3´-sialilactosa es al menos igual de elevada que la cantidad de 2´-fucosilactosa; y método para modular o estimular la proliferación de bifidobacterias en el intestino humano. CL2013002210A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161441451P 2011-02-10 2011-02-10

Publications (1)

Publication Number Publication Date
CL2013002210A1 true CL2013002210A1 (es) 2014-01-10

Family

ID=45809349

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013002210A CL2013002210A1 (es) 2011-02-10 2013-08-01 Formulación prebiótica para consumo humano que comprende 2´-fucosilactosa, 3´-sialilactosa y 6´-sialilactosa, en que la cantidad en peso de 3´-sialilactosa es al menos igual de elevada que la cantidad de 2´-fucosilactosa; y método para modular o estimular la proliferación de bifidobacterias en el intestino humano.

Country Status (19)

Country Link
US (3) US20140371173A1 (es)
EP (2) EP2672844B2 (es)
CN (2) CN103347405A (es)
AU (1) AU2012215042B2 (es)
BR (1) BR112013020108A2 (es)
CA (1) CA2825697A1 (es)
CL (1) CL2013002210A1 (es)
ES (2) ES2527200T5 (es)
IL (1) IL227487A (es)
MX (2) MX362129B (es)
MY (1) MY161034A (es)
PH (1) PH12013501501A1 (es)
PL (1) PL2672844T3 (es)
PT (1) PT2672844E (es)
RU (1) RU2586928C2 (es)
SG (1) SG192095A1 (es)
TW (1) TW201244640A (es)
WO (1) WO2012107865A2 (es)
ZA (1) ZA201306751B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013020108A2 (pt) 2011-02-10 2017-06-13 Nestec Sa modulação do crescimento de bifidobactérias usando uma combinação de oligossacarídeos encontrados no leite de ser humano
MY171851A (en) 2011-06-20 2019-11-04 Heinz Co Brands H J Llc Probiotic compositions and methods
US20150265661A1 (en) * 2012-04-13 2015-09-24 Trustees Of Boston College Prebiotic effect of sialyllactose
ES2572831T3 (es) 2012-09-14 2016-06-02 Abbott Laboratories Composiciones nutricionales para su uso en métodos para modular los niveles de corticosterona en individuos con estrés psicológico
EP3673909A1 (en) 2014-04-08 2020-07-01 Abbott Laboratories Nutritional compositions for use in treating enteric infection comprising human milk oligosaccharides
EP3209308B1 (en) * 2014-10-24 2022-08-03 Evolve Biosystems Inc. Activated bifidobacteria and methods of use thereof
RU2706963C2 (ru) * 2014-11-26 2019-11-21 Абботт Лаборэтриз Молочная смесь, содержащая олигосахариды грудного молока, полиненасыщенные жирные кислоты, нуклеотиды и лютеин
EP3223826A1 (en) * 2014-11-26 2017-10-04 Abbott Laboratories Infant formula with rrr-alpha-tocopherol, 2'-fucosyllactose, and a probiotic
US10987368B2 (en) 2014-12-08 2021-04-27 Glycom A/S Synthetic composition for preventing or treating CVD
EP3229812A4 (en) 2014-12-08 2018-10-03 Glycom A/S Synthetic composition for treating metabolic disorders
US10835544B2 (en) 2014-12-08 2020-11-17 Glycom A/S Synthetic composition for regulating satiety
US10881674B2 (en) 2014-12-08 2021-01-05 Glycom A/S Synthetic composition for treating metabolic disorders
PH12017550041B1 (en) * 2015-03-05 2022-08-05 Socia‰Ta‰ Des Produits Nestla‰ S A Compositions for use in improving stool consistency or frequency in infants or young children
CN108348535B (zh) 2015-10-28 2021-08-31 格礼卡姆股份公司 用于调节脑功能和行为的合成组合物和方法
ES2950489T3 (es) 2015-10-28 2023-10-10 Glycom As Composición sintética y método para modular los trastornos de la emoción y del ánimo
EP3389404B1 (en) * 2015-12-15 2019-10-02 Société des Produits Nestlé S.A. Mixture of hmos
HRP20200892T1 (hr) 2016-06-21 2020-11-27 Arla Foods Amba Proces za proizvodnju poboljšanih prehrambenih proizvoda koji sadrže mliječni protein i mliječne saharide
WO2018020473A1 (en) 2016-07-28 2018-02-01 Fonterra Co-Operative Group Limited Dairy product and process
IL271112B2 (en) * 2017-06-21 2023-11-01 Abbott Lab Methods to increase the growth of beneficial bacteria in the digestive system
KR102741265B1 (ko) * 2017-11-30 2024-12-11 글리콤 에이/에스 미생물총 조절을 위한 인간 밀크 올리고당 및 그의 합성 조성물
EP3981256A4 (en) * 2019-06-05 2023-01-25 Morinaga Milk Industry Co., Ltd. COMPOSITION
JP7474596B2 (ja) * 2020-01-20 2024-04-25 森永乳業株式会社 新規ビフィドバクテリウム属細菌、および当該細菌を含む組成物、並びに当該細菌の増殖促進用の組成物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260280A (en) 1989-02-07 1993-11-09 Snow Brand Milk Products Co., Ltd. Bacterial toxin neutralizer
EP1255449B2 (en) † 2000-02-17 2016-06-08 Nestec S.A. Nutritional formulation containing prebiotic substances
AU2001238400A1 (en) * 2000-02-18 2001-08-27 Argose, Inc. Multivariate analysis of green to ultraviolet spectra of cell and tissue samples
US6913778B2 (en) 2001-12-21 2005-07-05 Wyeth Infant formula compositions comprising increased amounts of alpha-lactalbumin
US7867541B2 (en) * 2003-04-14 2011-01-11 Mead Johnson Nutrition Company Compositions and methods of formulation for enteral formulas containing sialic acid
CN1863463B (zh) * 2003-06-23 2011-05-04 雀巢技术公司 用于促进肠道屏障成熟的营养组合物
JP5236189B2 (ja) 2003-12-05 2013-07-17 チルドレンズ ホスピタル メディカル センター オリゴ糖組成物および感染症の治療における該組成物の使用
WO2007051475A1 (en) † 2005-11-04 2007-05-10 Arla Foods Amba A concentrate derived from a milk product enriched in naturally occurring sialyllactose and a process for preparation thereof
WO2007114683A1 (en) 2006-03-30 2007-10-11 N.V. Nutricia Milk oligosaccharides for stimulating the immune system
EP2060257A1 (en) * 2007-11-08 2009-05-20 Nestec S.A. Prevention and treatment of secondary infections following viral infection
EP2072052A1 (en) * 2007-12-17 2009-06-24 Nestec S.A. Prevention of opportunistic infections in immune-compromised subjects
NL2001377C2 (nl) † 2008-03-14 2009-09-15 Friesland Brands Bv Werkwijze voor het isoleren van siaalzuur bevattende oligosachariden, alsmede de hiermee verkrijgbare siaalzuur bevattende oligosachariden bevatttende samenstellingen.
WO2011012655A1 (en) * 2009-07-31 2011-02-03 Nestec S.A. Nutritional composition for breast-fed infants or pets with probiotics and selected nutrients
NL2004200C2 (en) * 2010-02-05 2011-08-08 Friesland Brands Bv Use of sialyl oligosaccharides in weight management.
CN102858191A (zh) * 2010-04-27 2013-01-02 N.V.努特里奇亚 6’-唾液酸化乳糖在婴儿和幼儿营养物中的用途
MX356184B (es) * 2010-12-31 2018-05-17 Abbott Lab Fórmulación pediátrica sintética que comprende un probiótico.
BR112013020108A2 (pt) 2011-02-10 2017-06-13 Nestec Sa modulação do crescimento de bifidobactérias usando uma combinação de oligossacarídeos encontrados no leite de ser humano

Also Published As

Publication number Publication date
PT2672844E (pt) 2015-02-04
PH12013501501A1 (en) 2019-10-07
EP2672844B1 (en) 2014-11-19
US20140371173A1 (en) 2014-12-18
CN103347405A (zh) 2013-10-09
IL227487A0 (en) 2013-09-30
BR112013020108A2 (pt) 2017-06-13
WO2012107865A3 (en) 2012-11-01
EP2792252A2 (en) 2014-10-22
MX2013009087A (es) 2013-09-13
US20150141367A1 (en) 2015-05-21
ES2527200T5 (es) 2022-12-29
PL2672844T3 (pl) 2015-04-30
RU2586928C2 (ru) 2016-06-10
SG192095A1 (en) 2013-08-30
EP2672844B2 (en) 2022-10-05
RU2013141449A (ru) 2015-03-20
MY161034A (en) 2017-04-14
MX345413B (es) 2017-01-27
IL227487A (en) 2015-10-29
US20120208782A1 (en) 2012-08-16
EP2792252B1 (en) 2018-09-12
WO2012107865A2 (en) 2012-08-16
ES2692533T3 (es) 2018-12-04
MX362129B (es) 2019-01-07
ES2527200T3 (es) 2015-01-21
AU2012215042B2 (en) 2016-01-14
TW201244640A (en) 2012-11-16
CA2825697A1 (en) 2012-08-16
CN104126749A (zh) 2014-11-05
EP2672844A2 (en) 2013-12-18
EP2792252A3 (en) 2015-03-25
ZA201306751B (en) 2015-05-27

Similar Documents

Publication Publication Date Title
CL2013002210A1 (es) Formulación prebiótica para consumo humano que comprende 2´-fucosilactosa, 3´-sialilactosa y 6´-sialilactosa, en que la cantidad en peso de 3´-sialilactosa es al menos igual de elevada que la cantidad de 2´-fucosilactosa; y método para modular o estimular la proliferación de bifidobacterias en el intestino humano.
EA201500535A1 (ru) Применение akkermansia muciniphila для лечения метаболических расстройств, увеличения расхода энергии и насыщения, снижения веса, композиция, фармацевтическая композиция, косметическая композиция и лекарственное средство
GT201300243A (es) Derivados de ácido 3-fenilpropiónico ramificados y su uso
BR112015003332A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112015003398A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
HN2011002406A (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
BR112012004806B8 (pt) composições imunogênicas que incluem moduladores da atividade de tlr, método para aumento da eficácia da referida composição e uso
BR112014016810A8 (pt) composições e métodos para tratamento de distúrbios metabólicos
BR112013022927A2 (pt) composição, métodos para substituir ou suplementar ou modificar uma microbiota do cólon de um sujeito, e para tratar um sujeito, e, uso de uma composição
ECSP11011278A (es) Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente.
ECSP13012379A (es) Pirimidinas y triazinas condensadas y su uso
MX341684B (es) Composicion para el uso en la prevencion y/o tratamiento de condiciones de la piel y enfermedades de la piel.
CR20120596A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
ECSP13012668A (es) Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso
UY31228A1 (es) Ariloxazoles sustituidos y su uso
CL2014001587A1 (es) Combinacion farmaceutica, composicion farmaceutica o kit farmaceutico que comprenden un inhibidor de dpp-4 y un analogo de glp-1; metodo para tratar y/o prevenir la obesidad o el sobrepesoo para reducir el peso corporal en un paciente humano.
CO2018002394A2 (es) Método para la inhibición de la absorción de lípidos y/o la promoción de excreción de lípidos usando d-psicosa
BR112012029746A2 (pt) composição para tratamento da pele, método para fornecer um efeito microbicida para pele e uso de uma combinação
BR112012020719A2 (pt) formulação herbicida método de tratamento de plantas com herbicida método de aumento da eficácia de uma formulação herbicida, e, uso de uma composição
CL2014000050A1 (es) Composicion farmaceutica en forma de solucion que comprende apomorfina, un codisolvente micible en agua, un antioxidante y agua, en la que el ph es superior a 4; procedimiento para fabricarla; y su uso como solucion inyectable en el tratamiento de la enfermedad de parkinson.
BR112014003640A8 (pt) métodos para perda de peso e composições cetogênicas
BR112013001297A2 (pt) composições farmacêuticas e respectivo uso e método de tratamento de doença ou condição respiratória
CL2014002845A1 (es) Compuestos derivados de pirazol inhibidores de sglt1; metodo para tratar la diabetes; composicion farmaceutica; uso del compuesto para el tratamiento de la diabetes tipo 1 y tipo 2.
BR112015011759A2 (pt) composição simbiótica e uso da mesma
MY171048A (en) Pharmaceutical composition for preventing or treating amyloid beta peptide-associated diseases or conditions